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Background: Dynamic changes in fibrosis markers occur under long-term antiviral treat-
ment (AVT) for chronic hepatitis B. We evaluated prognostic values of on-treatment liver 
stiffness (LS) compared to ultrasonography findings and determined its optimal cutoff.
Methods: The cumulative probability of hepatocellular carcinoma (HCC) was assessed 
among 880 patients receiving entecavir or tenofovir for ≥2 years. LS was measured using 
transient elastography.
Results: After ≥2 years’ AVT, the proportion of patients with cirrhosis on ultrasonography 
decreased from 54.7% to 44.9% and the mean LS decreased from 13.6 to 8.2 kPa (both 
p<0.001). However, unlike cirrhosis on ultrasonography before AVT (p<0.001), that after 
≥2 years’ AVT did not discriminate HCC risk (p=0.792). Using the Contal and 
O’Quigley’s method, pre-AVT and on-treatment LS of 12.0 and 6.4 kPa, respectively, 
were chosen as optimal cutoffs to successfully discriminate HCC risk (both p<0.001). 
However, through stratification using both pre-AVT and on-treatment LS, the prognosis 
was finally determined according to on-treatment LS of 6.4 kPa, regardless of pre-AVT LS 
of 12.0 kPa. Using on-treatment LS of 12 kPa suggested by Caucasians with CHB 
receiving long-term AVT, patients with higher LS were more likely to develop HCC 
than those with lower LS (p=0.017); however, there was no significant difference between 
those with on-treatment LS of 6.4–11.9 and ≥ 12.0 kPa (p=0.920).
Conclusion: For HCC risk stratification in patients receiving long-term AVT, on-treatment 
LS cutoff should be lowered to 6.4 kPa, which is more predictive than 12 kPa or cirrhosis on 
ultrasonography. Further studies are required for validation.
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Introduction
The overall prognosis of chronic hepatitis B virus (HBV) infection has improved 
primarily owing to long-term antiviral treatment (AVT) with potent oral nucleos(t) 
ide analogs (NUCs), such as entecavir (ETV) or tenofovir disoproxil fumarate 
(TDF), to prevent liver-disease progression and achieve to virological and biochem-
ical remission.1–4 However, as hepato-carcinogenesis is very complex based upon 
both host and viral factors,5–10 it is difficult to eradicate, and some patients show 
HCC development, which remains a major public health problem in HBV-endemic 
areas.11 Therefore, in addition to AVT, early detection of HCC by periodic surveil-
lance is of paramount importance to allow timely interventions with a curative 
intent.12–19
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Before the era of potent AVT, the serum HBV-DNA 
level was an important risk factor for HCC development.20 
However, because most patients taking potent NUCs can 
quickly achieve a complete virological response, its pre-
dictive performance had been substantially attenuated, 
especially in patients undergoing long-term NUC 
therapy;21,22 this explains the considerable discrepancies 
among predictive performances of various HCC risk 
scores among study populations. Therefore, the remaining 
fibrotic burden, rather than antiviral regimens and/or intra-
hepatic inflammatory activity, has become the most crucial 
factor for determining the risk of HCC development.23,24 
Given that active AVT-induced reversal of liver fibrosis is 
the key mechanism by which viral suppression induces 
favorable clinical outcomes, long-term NUC therapy can 
also reduce the fibrotic burden, as assessed when by liver 
stiffness (LS).25 Recently, Papatheodoridis et al24 showed 
that patients achieving an LS of <12 kPa in 5 years of AVT 
had a significantly lower risk of HCC development than 
those who did not achieve this LS cutoff. However, while 
gross ultrasonographic findings indicative of liver cirrhosis 
at baseline are also a strong predictor of HCC 
development,26 few studies have evaluated their predictive 
performances compared to that of on-treatment LS in 
patients receiving prolonged AVT.
This study assessed the prognostic value of on- 
treatment LS during long-term NUC therapy compared to 
those of gross ultrasonographic findings and established an 
optimal LS value for the prediction of HCC among 
patients with chronic hepatitis B (CHB).
Methods
Study Subjects
Between 2012 and 2018, treatment-naïve patients with 
CHB who had been taking ETV or TDF for at least 2 
years in Severance Hospital, Seoul, Republic of Korea, 
were considered eligible for enrollment. The inclusion 
criteria were 1) age ≥19 years, 2) reliable LS values both 
before starting AVT and at ≥2 years of AVT, and 3) avail-
able ultrasonography results both before starting AVT and 
at ≥2 years of AVT. LS was measured using transient 
elastography (TE; FibroScan®, EchoSens, Paris, France) 
with a standard protocol.27 Only LS values with at least 10 
valid measurements, a success rate of at least 60%, and an 
interquartile range (IQR)-to-median ratio of <30% were 
considered reliable. On-treatment LS value was defined as 
one assessed after ≥ 2 years of AVT. The exclusion criteria 
were 1) history of HCC or decompensated liver cirrhosis 
at enrollment; 2) co-infection with other hepatitis 
viruses; 3) history of organ transplantation; 4) HCC devel-
opment, hepatic decompensation, or death within 6 
months of enrollment; and 5) other significant medical 
illnesses.
The study protocol was consistent with the ethical 
guidelines of the 1975 Declaration of Helsinki and was 
approved by the institutional review board of Severance 
Hospital, Seoul, Korea. Patient consent was waived 
because it is a retrospective study design. Patient’s infor-
mation was replaced with research identification codes for 
patient data confidentiality.
Clinical Evaluation and Follow-Up
During follow-up, NUC therapy was continued, and all 
patients underwent routine laboratory testing and assays 
for measuring serum HBV-DNA levels and other viral 
markers every 3–6 months. Serum alanine aminotransfer-
ase (ALT) levels were measured using standard laboratory 
procedures with the upper limit of normal set at <40 IU/ 
mL. Furthermore, patients also underwent ultrasonogra-
phy and assays for measuring serum alpha-fetoprotein 
levels every 6 months to screen for HCC and portal 
hypertension-related complications.4,16,28 Liver cirrhosis 
based on ultrasonographical findings was defined when 
at least one of the following criteria was fulfilled; the 
presence of an irregular, nodular liver surface, highly 
coarse liver echotexture, a blunt liver edge, shrunken 
liver parenchyma, disturbed vascular architecture, or 
other findings suggestive of portal hypertension including 
splenomegaly (size >12 cm) and/or portosystemic 
collaterals.29–32
The primary endpoint of this study was HCC develop-
ment. HCC was diagnosed based on histological evidence 
or dynamic computed tomography and/or magnetic reso-
nance imaging findings (a nodule sized >1 cm with arterial 
hyper-vascularity and portal/delayed-phase washout).33–35 
The index date was the date of enrollment, while the time 
to HCC development was considered as the period 
between the index date and the date of HCC diagnosis or 
the end of follow-up in the absence of HCC development.
Statistical Analysis
Data are expressed as means ± standard deviations, med-
ians (IQRs), or numbers (%), as appropriate. Differences 
among continuous and categorical variables were exam-
ined for statistical significance by the Student’s t-test (or 
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the Mann–Whitney test, if appropriate) and chi-squared (or 
Fisher’s exact tests, if appropriate) test. Paired data were 
analyzed using McNemar’s or Wilcoxon signed-rank tests.
The cumulative risk of HCC development was eval-
uated using the Kaplan–Meier method, with compari-
sons using the Log rank test. Cox regression analysis 
was performed to assess the associations between the 
risk of HCC and each variable and to calculate hazard 
ratios (HRs) and 95% confidence intervals (CIs). 
Furthermore, Contal and O’Quigley’s method based 
on Log rank tests,36 an outcome-oriented method, was 
applied to determine an optimal LS cutoff before and 
during AVT for prognostication. Then, multivariable 
Cox-regression analysis was performed to determine 
the final prognostic factors associated with HCC 
development.
All statistical analyses were conducted using SAS, 
version 9.2 (SAS Institute), R (V.3.0, http://cran.r-pro 
ject.org/), and IBM® SPSS® Statistics for Windows, 
version 25.0 (IBM Corp., Armonk, NY, USA). Two- 
sided p-values < 0.05 were considered to indicate sta-
tistical significance.
Results
Clinical Characteristics of the Study 
Population After ≥2 Years of AVT
A total of 880 treatment-naïve CHB patients were ana-
lyzed; of these, 400 and 480 patients were treated with 
ETV and TDF, respectively. Their clinical characteristics 
after ≥2 years of AVT are described in Table 1. The mean 
age was 53.1 years, and the male was predominant 
(57.6%). Liver cirrhosis was identified by ultrasonography 
in 44.9% of patients. The mean ALT value and platelet 
count were 29.0 IU/mL and 170 ×103/uL, respectively, 
whereas the mean log10 HBV-DNA value was 1.3 IU/ 
mL. The mean on-treatment LS was 8.2 kPa. All patients 
had well-preserved liver function (Child-Pugh class A).
Changes in Parameters After ≥2 Years of 
AVT
Clinical characteristics of the study population before 
starting AVT are described in Table 2. Liver cirrhosis 
was detected in 54.7% of patients, and the mean LS was 
13.6 kPa. The mean ALT level and platelet count were 
114.0 IU/mL and 160 ×103/uL, respectively.
Table 1 Patients’ Clinical Characteristics Before Starting AVT and After ≥ 2 Years of AVT (n=880)
Variables Before Starting AVT After ≥ 2 Years of AVT
Age, years 49.9 ± 10.7 53.1± 10.5
Male 373 (42.4) 507 (57.6%)
Diabetes mellitus 112 (12.7) 134 (15.2%)
Liver cirrhosis* 481 (54.7) 395 (44.9%)
ALT, IU/mL 114 ± 269 29.0 ± 34.7
Total bilirubin, mg/dL 1.2 ± 2.0 0.9 ± 0.5
Albumin, mg/dL 4.1 ± 0.5 4.4 ± 0.4
Prothrombn time-INR 1.1 ± 0.2 1.0 ± 0.1
Platelet count, ×103/uL 160 ± 63 170 ± 64
HBeAg positivity 471 (53.5) 429 (50.6%)
HBV-DNA, log10 IU/mL 4.7 ± 2.5 1.3 ± 0.9
LS, kPa 13.6 ± 11.3 8.2 ± 5.9
Controlled attenuated parameter, dB/m 224 ± 57 240 ± 43
The proportion of normalized ALT after ≥ 2 years of AVT * 761 (85.2%)
The proportion of HBV-DNA < 20 IU/mL after ≥ 2 years of AVT 702 (79.8%)
Δ LS, kPa ** −5.4 ± 9.6
Δ Controlled attenuation parameter, dB/m ** 9.4 ± 41.8
Notes: Values are expressed as mean ± standard deviation or number (%). The delta is defined as the value after ≥ 2 years of AVT minus that before starting AVT. 
*P-value<0.001 by McNemar test; **P-value<0.001 by Wilcoxon signed rank test. 
Abbreviations: AVT, antiviral treatment; ALT, alanine aminotransferase; INR, international normalized ratio; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; LS, liver 
stiffness.
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After ≥2 years of AVT, serum HBV-DNA levels <20 
IU/mL were observed in 79.8% of patients. During 
long-term NUC therapy, the proportion of patients with 
normal serum ALT levels increased from 39.7% to 
85.2% (p<0.001). After ≥2 years of AVT, the LS 
decreased significantly by 5.4 kPa (p<0.001), and the 
proportion of patients with liver cirrhosis on ultrasono-
graphy also decreased from 54.7% to 44.9% (p<0.001) 
(Table 1).
Cumulative Probability of HCC 
Development According to Variables 
Before Starting AVT
Among 880 patients, 81 (9.2%) developed HCC. Table 
2 shows the comparison of variables between those 
who developed HCC and those who did not. To assess 
the prognostic significance of dynamic changes in vari-
ables through ≥2 years of AVT, we first analyzed the 
cumulative probability of HCC development according 
to values recorded before starting AVT. Using Contal 
and O’Quigley’s method, we proposed an optimal cut-
off value of pre-AVT LS of 12.0 kPa.36 The cumulative 
risk of HCC development was significantly higher in 
patients with pre-AVT LS of ≥12.0 kPa than in those 
with pre-AVT LS of <12.0 kPa (p<0.001) (Figure 1). 
Furthermore, patients with liver cirrhosis on 
ultrasonography before AVT were more likely to 
develop HCC than those without (p<0.001) 
(Figure 2A).
Cumulative Probability of HCC 
Development According to On- 
Treatment Variables After ≥2 Years of 
AVT and Overall Predictors for HCC 
Development
We stratified the cumulative risk of HCC development 
based on the fibrotic burden after ≥2 years of AVT. 
Likewise, using Contal and O’Quigley’s method, we 
identified an optimal cutoff value of on-treatment LS 
of 6.4 kPa.36 The cumulative risk of HCC development 
was significantly higher in patients with on-treatment LS 
of ≥6.4 kPa than in those with on-treatment LS of <6.4 
kPa (p<0.001; Figure 3). In contrast, liver cirrhosis on 
ultrasonography after ≥2 years of AVT, a prognostic 
factor in the previous study, did not have discriminatory 
ability in terms of HCC risk prediction (p=0.792; Figure 
2B), unlike liver cirrhosis on ultrasonography 
before AVT.
Thereafter, univariate analysis was performed to iden-
tify potential factors associated with HCC development. 
Univariate predictors with p values of < 0.05, including 
age, ALT levels ≥40 U/L, total bilirubin levels, albumin 
levels, platelet counts, and on-treatment LS of ≥6.4 kPa, 
Table 2 Comparisons of Clinical Characteristics Between Patient with HCC and Those without
Variables After ≥ 2 Years of AVT Patients with HCC (n=81) Patients without HCC 
(n=799)
p-value
Age, years 58.4 ± 8.4 52.6 ± 10.6 <0.001
Male 52 (64.2%) 455 (56.9%) 0.208
Diabetes mellitus 13 (16.0%) 121 (15.1%) 0.829
Liver cirrhosis 36 (44.4%) 359 (44.9%) 0.933
ALT, IU/mL 46.4 ± 80.5 27.2 ± 25.3 0.036
Total bilirubin, mg/dL 1.0 ± 0.7 0.9 ± 0.4 0.094
Albumin, mg/dL 4.2 ± 0.5 4.4 ± 0.3 0.001
Prothrombn time-INR 1.0 ± 0.1 1.0 ±0.1 0.552
Platelet count, ×103/uL 129 ± 44 174 ± 64 <0.001
HBeAg positivity 39 (51.3%) 390 (50.5%) 0.894
HBV-DNA, log10 IU/mL 1.1 ± 0.5 1.3 ± 0.9 0.057
LS, kPa 10.1 ± 5.3 8.0 ± 5.9 0.002
Controlled attenuated parameter, dB/m 249 ± 43 239 ± 42 0.033
Note: Values are expressed as mean ± standard deviation or number (%). 
Abbreviations: AVT, antiviral treatment; HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; INR, international normalized ratio; HBeAg, hepatitis B e antigen; 
HBV, hepatitis B virus; LS, liver stiffness.
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were entered into a multivariate Cox regression model. 
Finally, four variables—older age (adjusted HR [aHR] 
1.044, 95% CI 1.019–1.070; p<0.001), lower platelet 
counts (aHR 0.991, 95% CI 0.987–0.996; p<0.001), 
ALT levels ≥40 U/mL (aHR 1.947, 95% CI 1.158–3.276; 
p=0.012), and on-treatment LS ≥6.4 kPa (aHR 2.347, 
95% CI 1.296–4.250; p=0.005)—were identified as inde-
pendent prognostic factors for HCC development 
(Table 3).
Verification of Another Cutoff of On- 
Treatment LS After ≥2 Years of AVT
We tested the prognostic performance of another cutoff 
(12 kPa) of on-treatment LS that had been recently sug-
gested by Papatheodoridis et al to be a significant predictor 
of HCC development among Caucasians with CHB receiv-
ing long-term potent AVT.24 In our study population, 
patients with on-treatment LS of ≥12 kPa were also 
Figure 1 Kaplan–Meier analyses according to pre-AVT LS with a cutoff of 12.0 kPa. 
Abbreviations: AVT, antiviral treatment; LS, liver stiffness; HCC, hepatocellular carcinoma.
Figure 2 Kaplan–Meier analyses according to liver cirrhosis on ultrasonography before starting AVT (A) and after ≥ 2 years of AVT (B). 
Abbreviations: AVT, antiviral treatment; HCC, hepatocellular carcinoma.
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significantly more likely to develop HCC than those with 
on-treatment LS of <12 kPa (p=0.017) (Supplementary 
Figure 1A).
However, dividing the patients into three groups by on- 
treatment LS values (<6.4 kPa vs 6.4–11.9 kPa vs ≥12.0 
kPa) showed no significant differences in risk between 
those with an on-treatment LS of 6.4–11.9 kPa and ≥12.0 
kPa (p=0.920; Supplementary Figure 1B). However, 
patients with on-treatment LS of <6.4 kPa were still sig-
nificantly less likely to develop HCC (both p<0.001) than 
those with an on-treatment LS of 6.4–11.9 kPa or 
≥12.0 kPa.
Risk Stratification Based on LS Both 
Before Starting AVT and After ≥2 Years of 
AVT
We stratified our study population into four groups based 
on pre-AVT and on-treatment LS (Supplementary Figure 
2). Regardless of pre-AVT LS (≥12.0 vs <12 kPa), the 
prognosis was finally determined according to on- 
treatment LS, ie, ≥6.4 vs <6.4 kPa. Among patients with 
on-treatment LS≥6.4 kPa, there was no significant differ-
ence in the HCC risk according to pre-AVT LS (≥12.0 vs 
<12 kPa) (p=0.302). Likewise, among patients with on- 
treatment LS<6.4 kPa, there was no significant difference 
in the HCC risk according to pre-AVT LS (≥12.0 vs <12 
kPa) (p=0.961).
Furthermore, we tried to validate the prognostic sig-
nificance of on-treatment LS over pre-AVT LS among the 
independent cohort from Gangnam Severance Hospital, 
Seoul, Republic of Korea (n=458), where similar results 
were reproduced. Among patients with on-treatment 
LS≥6.4 kPa, there was no significant difference in the 
HCC risk according to pre-AVT LS (≥12.0 vs <12 kPa) 
(p=0.527). Likewise, among patients with on-treatment 
LS<6.4 kPa, there was no significant difference in the 
HCC risk according to pre-AVT LS (≥12.0 vs <12 kPa) 
(p=0.643).
Generation of the HCC Risk Prediction 
Model
We generated the HCC risk prediction model using 4 
significant variables shown in Table 3, ie, age, ALT, plate-
let count, and LS value; the regression coeffcient of each 
risk predictor from the multivariate Cox proportional 
hazards model was divided by that of age criteria (≥ 60 
vs < 60 years), which was the lowest value among those of 
4 variables, and then was rounded to an integer value to 
generate each score, respectively (Supplementary Table 1). 
Figure 3 Kaplan–Meier analysis according to on-treatment LS with a cutoff of 6.4 kPa after ≥ 2 years of AVT. 
Abbreviations: LS, liver stiffness; AVT, antiviral treatment; HCC, hepatocellular carcinoma.
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Then, the risk-scoring model was the sum of each score 
assigned to each key variable, providing the area under the 
receiver operating characteristic curve of 0.750 (95% CI 
0.670 ~ 0.830) to predict the HCC development at 3 years.
Discussion
Several HCC risk scores have been developed and vali-
dated in large cohorts of NUC-treated CHB patients.21,22 
Most models established in the era of potent AVT did not 
incorporate serum HBV-DNA levels. Conversely, para-
meters reflecting fibrotic burden, such as serum fibrosis 
markers, ultrasonography findings, and LS, have been 
always crucial components. Given that such indices can 
change dynamically through fibrosis regression during 
prolonged potent AVT,37 we aimed to identify an optimal 
cutoff for on-treatment LS for more accurate prognostica-
tion and to compare its usefulness to that of gross ultra-
sonography findings or other LS cutoffs.
In this study, we proposed a much lower cutoff of 6.4 kPa 
for on-treatment LS as a sentinel for HCC surveillance, 
approximately half of the conventional cutoffs (eg, 12 or 13 
kPa).38,39 Kim et al39 proposed the so-called concept of TE- 
defined subclinical cirrhosis for 13 kPa, indicative of a higher 
risk of HCC development among patients with LS ≥13 kPa. 
However, in that study by Kim et al,39 approximately 45% of 
enrolled patients did not receive AVT. Thus, our study provides 
more reliable data optimized for patients receiving long-term 
potent NUC therapy. In contrast, Papatheodoridis et al24 sug-
gested an on-treatment LS cutoff of 12 kPa for patients who 
had been receiving potent NUC therapy for 5 years. 
Stratification of the population showed that the prediction of 
HCC risk might also be feasible with an on-treatment LS cutoff 
of 12 kPa (p=0.017). However, as seen in Supplementary 
Figure 1B, when patients were stratified into three categories 
of on-treatment LS (6.3 kPa vs 6.4–11.9 kPa vs ≥12.0 kPa), 
stepwise discrimination of HCC risk was no longer observed as 
patients with high vs intermediate levels of on-treatment LS 
had similar HCC risks. Thus, because the identification of 
patients with negligible risk of HCC development is one of 
the primary goals of risk scoring systems, we propose that 
a lower on-treatment LS cutoff of 6.4 ka would be more 
appropriate for effective HCC surveillance.
Liver cirrhosis on ultrasonography before AVT was 
also a significant predictor for HCC development in our 
study, consistent with that in previous studies.5,22 
However, once patients undergo prolonged potent AVT, 
cirrhosis on ultrasonography during prolonged AVT no 
longer played a crucial role in HCC risk prediction. 
Although the proportion of patients with liver cirrhosis 
on ultrasonography significantly decreased by about 10% 
after prolonged potent AVT, the prognostic value of this 
gross finding was surpassed by those of microscopic char-
acteristics incorporated in LS. Consistent with our results, 
Papatheodoridis et al24 developed the SAGE-B score for 
patients receiving long-term AVT, which showed 
a similarly excellent prognostic performance even without 
including the variable of “cirrhosis.” Therefore, for cases 
involving discrepancies between TE and ultrasonography 
data in real-life practice, it would be more reasonable to 
make clinical decisions based on TE-based information.
Table 3 Risk Factors for the Development of Hepatocellular Carcinoma
Variables After ≥ 2 Years of AVT Univariate Analysis Multivariate Analysis
P-value Adjusted HR 95% CI P-value




ALT ≥ 40 U/mL 0.009 1.947 1.158 ~ 3.276 0.012
Total bilirubin 0.029 0.865 0.586 ~ 1.279 0.468
Albumin <0.001 0.673 0.407 ~ 1.114 0.123
Prothrombin time-INR 0.505
Platelet count <0.001 0.991 0.987 ~ 0.996 <0.001
HBeAg positivity 0.998
HBV-DNA, log10 IU/mL 0.288
LS ≥ 6.4 kPa <0.001 2.347 1.296 ~ 4.250 0.005
Abbreviations: AVT, antiviral treatment; HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; INR, international normalized ratio; HBeAg, hepatitis B e 
antigen; HBV, hepatitis B virus; LS, liver stiffness.
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Our study has several strengths and clinical implications. 
First, the homogeneous study population, large sample size 
(n=880), and sufficient number of HCC events (9.2%) as well 
as the long-term follow-up enhanced the statistical reliability. 
Moreover, to support scientific validity, cutoff points for con-
tinuous variables were determined using an outcome-oriented 
statistical method rather than arbitrary determination or simple 
adoption of previously suggested cutoffs. Second, although LS 
may not perfectly reflect the degree of change in histological 
fibrosis, the gold standard for predicting prognosis in chronic 
liver diseases, among CHB patients receiving prolonged AVT, 
LS remains the most widely validated tool by which clinically 
relevant information can be obtained easily and non- 
invasively in real-life practice. Third, from a practical view-
point, we selected the time point of ≥2 years of AVT to re- 
assess the risk of HCC based on the study by Chon et al37 
which indicated significant dynamic changes in HCC risk 
scores occur for up to 2 ~ 3 years after AVT initiation. In 
contrast, Papatheodoridis et al24 focused on patients who had 
been receiving potent AVT for at least 5 years. However, 
considering that the annual risk of HCC development usually 
exceeds 1.5% in patients with HBV-related cirrhosis and that 
the proportion of such patients among our study population 
was approximately 50%, a minimum follow-up duration of 5 
years was too long in terms of our practice milieu.
Furthermore, when our study population was stratified 
into four groups based on both pre-AVT and on-treatment LS, 
the prognosis was determined according to on-treatment LS 
(≥6.4 vs <6.4 kPa), regardless of the pre-AVT LS (≥12.0 vs 
<12 kPa). Thus, patients with relatively higher LS before 
AVT may have a significantly lower risk of HCC occurrence 
provided that they showed a good response in terms of 
fibrosis regression due to long-term potent AVT. 
Conversely, patients with a relatively favorable fibrotic status 
before AVT may have a significantly higher risk if they show 
a suboptimal response despite prolonged potent AVT. Our 
results indicate the need for the re-assessment of HCC risk 
during long-term NUC therapy to develop personalized HCC 
surveillance strategies.
This study also has several limitations. First, since it was 
conducted from a single tertiary referral hospital-based 
cohort in the Republic of Korea, our results were potentially 
subject to selection bias. Nevertheless, a homogeneous study 
population, a statistically reliable sample size, event number, 
and follow-up duration, and an outcome-oriented statistical 
method could help overcome this drawback. In the similar 
context, >98% of patients are infected with HBV genotype 
C through vertical transmission, both of which were 
associated with a higher risk of HCC development.3 Thus, 
these results may not be generalizable to the full spectrum of 
the population with chronic HBV infection. However, 
because the overall virological response rates for potent 
AVT are similar among HBV genotypes, in contrast to 
those for pegylated interferon therapy, our results are likely 
to be reproduced in other countries.3 Second, the incorpora-
tion of new biomarkers for CHB (eg, serum quantitative 
HBsAg, serum hepatitis B core-related antigen, serum HBV- 
RNA, or specific HBV mutants) into the model may have 
provided more precise predictions.40–43 Last, along with an 
issue of how to identify so called, a high-risk group, the 
development of a diagnostic modality to detect early de- 
novo carcinogenesis with high sensitivity and specificity 
should be required in the future researches.44–46
In conclusion, the on-treatment LS cutoff for the appro-
priate stratification of HCC risk among patients receiving 
long-term potent AVT should be lowered to 6.4 kPa, 
approximately half of the conventional cutoff. Liver cirrho-
sis on ultrasonography after ≥2 years of AVT did not predict 
HCC development. Therefore, for cases with discrepancies 
between TE and ultrasonography data, decision-making 
based on TE-based information might be more reasonable. 
Further studies are required for external validation.
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